Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10711780 | 0.84 | CYP2D6 (0.44) | MAPTHSD17B10ALDH1A1KDM4CCYP2D6 | |
| SCHEMBL30020219 | 0.80 | ALDH1A1 (0.62) | MAPTHSD17B10ALDH1A1KDM4CTP53 | |
| SCHEMBL2930553 | 0.79 | HTR1A (0.50) | MAPTALDH1A1TP53LMNASIRT2 | |
| SCHEMBL28662503 | 0.77 | ALDH1A1 (0.54) | MAPTHSD17B10ALDH1A1CYP2D6IDO1 | |
| SCHEMBL2672584 | 0.75 | HSD17B10 (0.47) | MAPTHSD17B10ALDH1A1IDO1 | |
| SCHEMBL13846776 | 0.74 | CA2 (0.69) | MAPTALDH1A1LMNAPOLB | |
| SCHEMBL30019852 | 0.73 | MAPT (0.60) | MAPTHSD17B10ALDH1A1KDM4CLMNA | |
| SCHEMBL13045133 | 0.72 | ALDH1A1 (0.61) | MAPTHSD17B10ALDH1A1CYP2D6 | |
| SCHEMBL7209808 | 0.71 | CA2 (0.46) | MAPTALDH1A1POLBUSP2 | |
| SCHEMBL27897675 | 0.71 | IDO1 (0.46) | MAPTALDH1A1CYP2D6IDO1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-1778236-B1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1778236-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014394-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025405-A1 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025405-A1 | Modified pyrimidine glucocorticoid receptor modulators | NR3C1, NR3C2, TYMS | MAPT 4208/4885HSD17B10 1568/4885ALDH1A1 3275/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | MAPT 4599/4885HSD17B10 634/4885ALDH1A1 242/4885 |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, TYMS | MAPT 4208/4885HSD17B10 1568/4885ALDH1A1 3275/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | MAPT 4599/4885HSD17B10 634/4885ALDH1A1 242/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | MAPT 4599/4885HSD17B10 634/4885ALDH1A1 242/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | MAPT 4599/4885HSD17B10 634/4885ALDH1A1 242/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | MAPT 4599/4885HSD17B10 634/4885ALDH1A1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.